Exfoliation glaucoma is a serious eye condition that requires careful management to prevent vision loss. Treatment focuses on lowering eye pressure, slowing disease progression, and preserving the quality of life for patients. Because this form of glaucoma often progresses faster and presents with higher pressure readings than other types, doctors typically recommend more aggressive monitoring and intervention.
How Treatment Approaches Differ in Exfoliation Glaucoma
When someone receives a diagnosis of exfoliation glaucoma, also called pseudoexfoliation glaucoma, their doctor immediately begins considering a treatment plan tailored to this specific type of secondary glaucoma. Unlike primary open-angle glaucoma, exfoliation glaucoma tends to cause higher eye pressure levels and shows greater fluctuations throughout the day. These characteristics mean that treatment must be more intensive from the start, with the goal of achieving very low pressure readings to slow down the damage to the optic nerve[1][3].
The disease develops when abnormal protein material, along with pigment from the iris, accumulates in the eye’s drainage system called the trabecular meshwork. This blockage prevents fluid from leaving the eye properly, causing pressure to build up[5]. Because this process is progressive and difficult to reverse, the treatment approach must address both the immediate pressure problem and the long-term management of a condition that may worsen over time.
Importantly, exfoliation glaucoma primarily affects older adults, typically those over 60 years of age. The estimated number of people worldwide living with this condition ranges between 5 and 6 million[3]. Because these patients may also have other health conditions related to aging, treatment plans need to account for overall health, potential medication interactions, and the ability to follow complex treatment regimens.
Standard Medical Treatment Approaches
The first line of treatment for exfoliation glaucoma typically involves prescription eye drops designed to lower intraocular pressure (IOP), which is the pressure inside the eye. The goal is not just to reduce pressure, but to achieve a target pressure that is low enough to prevent further damage to the optic nerve. Research suggests that maintaining a long-term average pressure below 17 mmHg, combined with good control of pressure fluctuations throughout the 24-hour period, is necessary to minimize disease progression[3][15].
Prostaglandin analog medications, such as latanoprost, travoprost, and bimatoprost, are commonly prescribed as initial therapy. These medications work by increasing the drainage of fluid from the eye through an alternative pathway. They are typically used once daily, usually in the evening, which makes them convenient for patients who may need help administering their drops. An important advantage of these medications is that they do not cause the systemic side effects associated with some other glaucoma medications, such as effects on the heart or lungs[15].
Clinical studies have shown that prostaglandin analogs provide somewhat greater pressure reduction in exfoliation glaucoma compared to older medications like timolol, and they also help reduce the fluctuation in pressure throughout the day[15]. However, because exfoliation glaucoma requires particularly aggressive pressure lowering, many patients need more than one medication to reach their target pressure.
Fixed-dose combination eye drops, which contain two different medications in a single bottle, are frequently used in exfoliation glaucoma management. These combinations improve patient adherence to treatment because they reduce the number of times someone needs to apply drops each day. They also minimize exposure to preservatives found in eye drops, which can cause irritation and damage to the surface of the eye over time—a concern particularly relevant for elderly patients who may have dry eye problems[3][15].
Beta blocker medications, such as timolol, are another class of drugs used to treat exfoliation glaucoma. These work by reducing the production of fluid inside the eye. However, doctors must be cautious when prescribing beta blockers to older patients because these medications can affect heart rate and breathing, potentially worsening conditions like asthma or heart disease. The tolerability of beta blockers tends to decline with age[3].
Medical treatment for exfoliation glaucoma is typically long-term and requires consistent use. Patients must understand that stopping their medications can lead to rapid increases in eye pressure and accelerated vision loss. Despite the best medical therapy, some patients will experience disease progression and require additional interventions.
Laser Treatment Options
When eye drops alone do not adequately control eye pressure, or when patients struggle with medication adherence, laser treatment becomes an important option. Two main types of laser therapy are used in exfoliation glaucoma: argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT)[3][4].
Both procedures work by applying laser energy to the trabecular meshwork—the drainage system of the eye—to improve fluid outflow and lower pressure. SLT is increasingly preferred because it causes less thermal damage to the surrounding tissue and can potentially be repeated if the effect wears off over time. The laser treatment can provide moderate reduction in eye pressure and serves as a helpful addition to medication therapy[4].
However, laser treatment in exfoliation glaucoma has some limitations. The pressure-lowering effect may not last as long in patients with exfoliation glaucoma compared to those with primary open-angle glaucoma. Studies suggest that the effectiveness of SLT might diminish more quickly in these patients, meaning that additional treatments or surgery may eventually be needed[4][10].
One significant advantage of laser therapy is that it temporarily removes some of the abnormal exfoliation material and pigment from the drainage system. While this effect is not permanent—the material continues to accumulate over time—it can provide meaningful pressure reduction for months or even years in some patients[3].
Surgical Treatment Methods
Because exfoliation glaucoma often presents with advanced damage and tends to progress despite medical and laser therapy, many patients eventually require surgical intervention. The choice of surgery depends on the severity of the disease, the patient’s overall health, and whether they also need cataract surgery.
Minimally invasive glaucoma surgery (MIGS) represents a newer approach that offers significant advantages for patients with mild to moderate exfoliation glaucoma. These procedures are less invasive than traditional surgeries, have quicker recovery times, and carry lower risks of complications. Common MIGS options include goniotomy, placement of a microstent in the trabecular meshwork, and gonioscopy-assisted transluminal trabeculotomy (GATT)[4][10].
The microstent works by creating a bypass channel through the blocked trabecular meshwork, allowing fluid to drain more effectively. GATT is becoming increasingly important for moderate to severe cases because it directly addresses the underlying problem by removing the blocked trabecular meshwork tissue, allowing for more effective fluid drainage[10]. This procedure has shown promising results with lower complication rates than traditional filtering surgeries.
For advanced exfoliation glaucoma that does not respond to MIGS procedures, traditional surgeries remain the gold standard. Trabeculectomy is a procedure that creates a new drainage pathway by making a small opening in the white part of the eye, allowing fluid to bypass the blocked natural drainage system. A small reservoir, called a bleb, forms under the eyelid where fluid collects before being absorbed by surrounding tissue[3][4].
Other surgical options include deep sclerectomy, viscocanalostomy, and trabecular aspiration. These procedures aim to improve drainage through different mechanisms. Each has its own advantages and risks, and the choice depends on individual patient factors[3].
Tube shunt surgery involves implanting a small tube that drects fluid from inside the eye to a reservoir placed on the surface of the eye. This surgery is often reserved for cases where other procedures have failed or are not suitable. While tube shunts provide significant pressure reduction, they come with risks including tube-related complications, corneal damage, infection, and erosion of the tube through the tissue[4][10].
An important consideration in exfoliation glaucoma surgery is that many patients also have cataracts—clouding of the eye’s natural lens. Whenever possible, combining cataract removal with glaucoma surgery is beneficial. Removing the cataract alone can sometimes help lower eye pressure and may make the drainage system more accessible for treatment. Studies have reported that after cataract extraction, the intraocular pressure may be easier to control[4][14].
Treatment in Clinical Trials
While standard treatments for exfoliation glaucoma focus on lowering eye pressure through medications, laser therapy, and surgery, researchers are actively investigating new approaches that might offer better outcomes or target the underlying disease process more directly. These investigational treatments are being tested in clinical trials at various stages of development.
Clinical trials follow a structured pathway with different phases. Phase I trials primarily assess safety and help determine appropriate doses in small groups of participants. Phase II trials expand to larger groups to evaluate whether the treatment works and to gather more information about side effects. Phase III trials compare the new treatment directly with standard care in large populations to definitively establish effectiveness and safety.
For exfoliation glaucoma specifically, much of the research in clinical trials focuses on understanding the genetic and molecular mechanisms that cause the abnormal protein material to accumulate. Studies have identified variants in a gene called LOXL1 as a major risk factor for developing exfoliation syndrome and glaucoma[2][6]. This gene is involved in the metabolism of elastin and other components of the extracellular material that forms the characteristic deposits seen in this condition.
Understanding the role of LOXL1 and related pathways has opened potential avenues for developing therapies that could prevent or slow the accumulation of exfoliation material. While specific drug candidates targeting these pathways have not yet reached advanced clinical trials for exfoliation glaucoma treatment, this area represents an important frontier in research.
Some clinical trials are investigating whether certain medications already used for other conditions might have beneficial effects in exfoliation glaucoma. Researchers are exploring therapies that address oxidative stress, inflammation, and abnormal protein accumulation—all processes believed to play a role in the disease. These trials are examining whether such interventions could complement pressure-lowering treatments by addressing the underlying cause of the drainage system blockage.
Clinical trials are also evaluating new surgical devices and techniques designed specifically for eyes with exfoliation glaucoma. Because these eyes have unique anatomical challenges, including weak zonules and heavy pigment deposits, specialized approaches may offer advantages over standard procedures. Some trials are assessing novel drainage implants, modified laser protocols, or combinations of treatments aimed at achieving better long-term pressure control with fewer complications.
Patients interested in participating in clinical trials for glaucoma can discuss options with their eye doctor or search for trials in their region. Clinical trials are conducted in many countries, including the United States, throughout Europe, and other regions worldwide. Eligibility for trials depends on many factors, including the stage of disease, previous treatments, and overall health status.
Most Common Treatment Methods
- Medication (Eye Drops)
- Prostaglandin analogs such as latanoprost, travoprost, and bimatoprost, used once daily to increase fluid drainage from the eye[15]
- Beta blockers like timolol, used to reduce fluid production, though caution is needed in elderly patients with heart or lung conditions[3][15]
- Fixed-dose combination drops containing two medications to improve adherence and reduce preservative exposure[3]
- Long-term daily use required, with target pressure typically below 17 mmHg to prevent progression[3][15]
- Laser Therapy
- Selective laser trabeculoplasty (SLT) to improve drainage through the trabecular meshwork[4][10]
- Argon laser trabeculoplasty (ALT) as an alternative approach[3]
- Can provide moderate pressure reduction and help remove exfoliation material temporarily[3]
- Effect may diminish more quickly in exfoliation glaucoma compared to other types[4][10]
- Minimally Invasive Glaucoma Surgery (MIGS)
- Goniotomy to create openings in the drainage system[4][10]
- Microstent implantation to bypass blocked trabecular meshwork[10]
- Gonioscopy-assisted transluminal trabeculotomy (GATT) to remove blocked tissue[10]
- Less invasive with quicker recovery and lower complication rates than traditional surgery[4][10]
- Best suited for mild to moderate disease[4]
- Traditional Glaucoma Surgery
- Trabeculectomy to create a new drainage pathway with a filtering bleb[3][4]
- Tube shunt surgery for cases where other procedures have failed[4][10]
- Deep sclerectomy and viscocanalostomy as alternative drainage procedures[3]
- Reserved for advanced disease or when other treatments are insufficient[4]
- Higher complication risks but significant pressure reduction[4]
- Combined Cataract and Glaucoma Surgery